These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19571674)

  • 1. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
    Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
    Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
    Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
    Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
    Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
    Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
    Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
    Golubovskaya V; O'Brien S; Ho B; Heffler M; Conroy J; Hu Q; Wang D; Liu S; Cance WG
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1613-31. PubMed ID: 25656374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
    Pathania D; Kuang Y; Sechi M; Neamati N
    Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
    Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
    Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
    O'Brien S; Golubovskaya VM; Conroy J; Liu S; Wang D; Liu B; Cance WG
    Oncotarget; 2014 Sep; 5(17):7945-59. PubMed ID: 25277206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
    Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
    Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
    Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
    Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
    Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
    Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.
    Heffler M; Golubovskaya VM; Conroy J; Liu S; Wang D; Cance WG; Dunn KB
    Anticancer Agents Med Chem; 2013 May; 13(4):584-94. PubMed ID: 22934709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
    Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
    Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.